New insider activity at Artivion ( (AORT) ) has taken place on February 25, 2026.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Artivion’s top leadership team has collectively unloaded a notable amount of company stock in a series of insider transactions. EVP, COO, CFO & Treasurer Lance Berry sold 9,466 shares for $347,255, while VP & CAO Amy Horton sold 2,561 shares for $94,673. SVP & GC Jean Holloway disposed of 4,747 shares worth $175,239, and President & CEO James Mackin executed the largest trade, selling 34,898 shares for $1,285,127. CCO John E Davis sold 5,848 shares for $215,846, and SVP, Clinical & MD Affairs Marshall S. Stanton sold 3,682 shares for $135,990. Together, these transactions highlight substantial selling activity across Artivion’s executive ranks.
Recent Updates on AORT stock
Artivion shares reacted to a strong Q4 and 2025 update, where double‑digit revenue and faster EBITDA growth were driven by stent grafts and On‑X valves, though reported results were dampened by a one‑time Italian reimbursement charge and lingering cyber and tissue headwinds. A notable price‑target trim stemmed from this masked profitability, conservative guidance assuming no tissue growth and only modest BioGlue gains, and recognition that higher CapEx, R&D and commercialization risks for AMDS and NEXUS could temper near‑term upside despite solid long‑term growth prospects, including a new decade‑long Chord‑X registry to build evidence for broader structural heart adoption.
Spark’s Take on AORT Stock
According to Spark, TipRanks’ AI Analyst, AORT is a Neutral.
The score is driven primarily by improving financial performance and a strong, margin-expansion-focused 2026 outlook from the earnings call. This is tempered by mixed cash-flow quality (free cash flow negative in 2025), bearish technical momentum, and limited valuation support from a negative P/E and no dividend yield data.
To see Spark’s full report on AORT stock, click here.
More about Artivion
YTD Price Performance: -22.50%
Average Trading Volume: 383,079
Technical Sentiment Signal: Buy
Current Market Cap: $1.69B